| Not Yet Recruiting | A Clinical Study of V540A in Healthy Female Participants (V540A-005) Healthy | Phase 2 | 2026-07-20 |
| Recruiting | A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Malignant Neoplasm, Carcinoma, Merkel Cell, Lymphoma | Phase 1 / Phase 2 | 2026-06-30 |
| Not Yet Recruiting | A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadon Healthy | Phase 1 | 2026-05-18 |
| Not Yet Recruiting | A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy A Healthy | Phase 1 | 2026-05-11 |
| Not Yet Recruiting | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronida Non-small Cell Lung Cancer | Phase 3 | 2026-05-11 |
| Not Yet Recruiting | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse | Phase 1 / Phase 2 | 2026-05-07 |
| Not Yet Recruiting | A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018) Healthy | Phase 1 | 2026-05-01 |
| Recruiting | A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) Lung Neoplasm Malignant | Phase 1 / Phase 2 | 2026-04-30 |
| Not Yet Recruiting | Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) Psoriatic Arthritis | Phase 2 | 2026-04-22 |
| Not Yet Recruiting | A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPAR Carcinoma, Renal Cell | Phase 3 | 2026-04-17 |
| Recruiting | A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) Bladder Cancer | Phase 3 | 2026-04-15 |
| Not Yet Recruiting | Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014) Hepatic Insufficiency | Phase 1 | 2026-04-07 |
| Not Yet Recruiting | A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerati Colitis Ulcerative, Ulcerative Colitis | Phase 2 | 2026-03-30 |
| Recruiting | A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK- Cytomegalovirus Prophylaxis | Phase 1 | 2026-03-30 |
| Recruiting | A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) Oesophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2026-03-27 |
| Recruiting | Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) Von Hippel-Lindau Disease, Carcinoma, Renal Cell | Phase 3 | 2026-03-23 |
| Active Not Recruiting | A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041) Healthy | Phase 1 | 2026-03-23 |
| Recruiting | MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) Non-small Cell Lung Cancer | Phase 3 | 2026-03-18 |
| Recruiting | A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) Healthy | Phase 1 | 2026-03-18 |
| Recruiting | A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affe Healthy | Phase 1 | 2026-03-06 |
| Recruiting | A Study of MK-7240 in Healthy Participants (MK-7240-009) Healthy | Phase 1 | 2026-03-05 |
| Recruiting | A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002) Healthy | Phase 1 | 2026-03-04 |
| Recruiting | A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) Chronic Kidney Failure, End-Stage Renal Disease, Renal Impairment | Phase 1 | 2026-03-02 |
| Recruiting | A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 | 2026-02-19 |
| Recruiting | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) Ovarian Neoplasms, Ovarian Cancer | Phase 3 | 2026-02-16 |
| Recruiting | KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab Bladder Cancer | Phase 1 / Phase 2 | 2026-02-09 |
| Active Not Recruiting | A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011) Healthy | Phase 1 | 2026-02-06 |
| Recruiting | A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Ca Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | 2026-01-29 |
| Active Not Recruiting | A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-01 Healthy | Phase 1 | 2026-01-22 |
| Recruiting | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-lin Cervical Cancer | Phase 3 | 2026-01-19 |
| Recruiting | A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) Pneumococcal Infection | Phase 1 | 2026-01-13 |
| Active Not Recruiting | A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039) Healthy | Phase 1 | 2025-12-29 |
| Recruiting | A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) Diabetes Mellitus, Type 2 | Phase 1 | 2025-12-22 |
| Recruiting | KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Canc Malignant Neoplasm | Phase 2 | 2025-12-19 |
| Active Not Recruiting | A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010) Healthy | Phase 1 | 2025-12-18 |
| Recruiting | A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591 Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Phase 2 / Phase 3 | 2025-12-18 |
| Recruiting | A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) Malignant Neoplasm | Phase 1 | 2025-12-16 |
| Recruiting | A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Smal Squamous Non-small Cell Lung Cancer | Phase 2 | 2025-12-12 |
| Recruiting | A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) Bladder Cancer, Urinary Bladder Neoplasms | Phase 1 / Phase 2 | 2025-12-09 |
| Active Not Recruiting | A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022) Healthy | Phase 1 | 2025-12-08 |
| Recruiting | A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) Neoplasm Malignant | Phase 2 | 2025-12-04 |
| Recruiting | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant The Renal Cell Carcinoma | Phase 3 | 2025-11-26 |
| Completed | A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016) Healthy | Phase 1 | 2025-11-19 |
| Recruiting | A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) Hyperlipidemia | Phase 3 | 2025-11-11 |
| Recruiting | A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 3 | 2025-11-10 |
| Recruiting | A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017) Healthy, Hepatic Impairment | Phase 1 | 2025-11-05 |
| Completed | A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004) Healthy | Phase 1 | 2025-10-28 |
| Recruiting | A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorde Insomnia | Phase 3 | 2025-10-09 |
| Recruiting | A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer Non-small Cell Lung Cancer | Phase 3 | 2025-10-08 |
| Recruiting | A Study of V118E in Healthy Participants (V118E-003) Healthy | Phase 1 | 2025-10-08 |
| Recruiting | A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) Arthritis, Rheumatoid | Phase 2 | 2025-10-08 |
| Completed | A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061) Healthy | Phase 1 | 2025-09-26 |
| Recruiting | A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) Radiographic Axial Spondyloarthritis | Phase 2 | 2025-09-26 |
| Recruiting | Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003) Diabetes Mellitus, Type 2 | Phase 1 | 2025-09-22 |
| Completed | A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015) Hepatic Impairment, Healthy Participants | Phase 1 | 2025-09-19 |
| Completed | A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006) Healthy | Phase 1 | 2025-09-17 |
| Recruiting | A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygo Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 2 / Phase 3 | 2025-08-21 |
| Completed | A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023) Hepatic Insufficiency | Phase 1 | 2025-08-20 |
| Completed | A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039) Healthy | Phase 1 | 2025-08-18 |
| Completed | A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014) Healthy | Phase 1 | 2025-08-12 |
| Recruiting | A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) Malignant Neoplasm | Phase 2 | 2025-08-11 |
| Recruiting | A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 3 | 2025-07-31 |
| Recruiting | Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2025-07-30 |
| Recruiting | A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) Metastatic Neoplasm | Phase 1 | 2025-07-23 |
| Recruiting | A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) Breast Neoplasms | Phase 3 | 2025-07-21 |
| Recruiting | Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Diseas Renal Cell Carcinoma | Phase 1 / Phase 2 | 2025-07-20 |
| Recruiting | A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) Early Alzheimer's Disease | Phase 2 | 2025-07-16 |
| Recruiting | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Canc Colon Adenocarcinoma, Rectal Adenocarcinoma | Phase 3 | 2025-07-16 |
| Recruiting | MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) HIV Infection | Phase 1 | 2025-07-09 |
| Completed | A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040) Healthy | Phase 1 | 2025-07-03 |
| Recruiting | A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic C Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | 2025-07-03 |
| Recruiting | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms | Phase 3 | 2025-06-30 |
| Recruiting | A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1) Healthy | Phase 3 | 2025-06-11 |
| Active Not Recruiting | Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) Hidradenitis Suppurativa | Phase 2 | 2025-06-09 |
| Recruiting | A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/I Malignant Melanoma | Phase 2 | 2025-05-29 |
| Recruiting | Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non- Lung Neoplasm | Phase 2 | 2025-05-28 |
| Recruiting | A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-0 Malignant Neoplasm | Phase 1 / Phase 2 | 2025-05-26 |
| Recruiting | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembro Endometrial Cancer | Phase 3 | 2025-05-22 |
| Completed | A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Ve Healthy | Phase 1 | 2025-05-16 |
| Recruiting | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) Prostate Cancer, Prostatic Neoplasms | Phase 3 | 2025-05-13 |
| Completed | A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009) Hepatic Impairment, Healthy Participants | Phase 1 | 2025-05-13 |
| Completed | A Study to Evaluate the Effect of Formulation and Food on Calderasib (MK-1084) in Healthy Adult Participants ( Healthy | Phase 1 | 2025-05-13 |
| Recruiting | A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Carcinoma, Non-Small-Cell Lung | Phase 2 | 2025-05-13 |
| Active Not Recruiting | A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY Pulmonary Arterial Hypertension | Phase 2 | 2025-05-12 |
| Completed | A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012) Healthy | Phase 1 | 2025-04-28 |
| Completed | A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-47 Malignant Neoplasm | Phase 1 | 2025-04-23 |
| Recruiting | Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) Hypertension, Pulmonary | Phase 2 | 2025-04-16 |
| Recruiting | A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) Ovarian Cancer Recurrent | Phase 1 / Phase 2 | 2025-04-15 |
| Completed | A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009) Healthy, HIV Pre-exposure Prophylaxis | Phase 1 | 2025-04-15 |
| Active Not Recruiting | A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Hum Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Phase 2 | 2025-04-14 |
| Recruiting | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Pred Lymphoma, Large B-Cell, Diffuse | Phase 2 | 2025-04-11 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | Phase 3 | 2025-04-09 |
| Completed | A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010) Healthy, Renal Impairment | Phase 1 | 2025-04-07 |
| Completed | A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End- Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic | Phase 1 | 2025-04-07 |
| Completed | A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035) Healthy | Phase 1 | 2025-04-02 |
| Active Not Recruiting | A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) Gastrointestinal Cancer | Phase 2 | 2025-04-01 |
| Recruiting | A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced N Non-small Cell Lung Cancer | Phase 2 | 2025-03-30 |
| Completed | A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035) Healthy | Phase 1 | 2025-03-28 |
| Withdrawn | A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Nega Early Triple Negative Breast Cancer | Phase 2 | 2025-03-26 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002 Advanced Solid Tumors, Malignant Neoplasm | Phase 1 / Phase 2 | 2025-03-25 |
| Recruiting | Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475- Lung Neoplasm Malignant | Phase 2 | 2025-03-20 |
| Recruiting | Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Breast Neoplasms, Breast Cancer | Phase 2 | 2025-03-20 |
| Completed | A Study of MK-8527 in Healthy Adult Participants (MK-8527-013) Healthy | Phase 1 | 2025-03-19 |
| Recruiting | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK Triple Negative Breast Neoplasms | Phase 3 | 2025-03-16 |
| Recruiting | A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ | Phase 2 | 2025-03-11 |
| Completed | A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants ( Healthy | Phase 1 | 2025-02-27 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Partic Small Cell Lung Cancer | Phase 1 / Phase 2 | 2025-02-27 |
| Recruiting | Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer T Breast Neoplasms, Breast Cancer | Phase 1 / Phase 2 | 2025-02-26 |
| Completed | A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants Healthy | Phase 1 | 2025-02-21 |
| Completed | A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005) Healthy | Phase 1 | 2025-02-10 |
| Recruiting | A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubic Diffuse Large B-Cell Lymphoma | Phase 3 | 2025-01-27 |
| Withdrawn | A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants Neoplasm Metastasis | Phase 1 / Phase 2 | 2025-01-15 |
| Completed | A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034) Healthy | Phase 1 | 2025-01-02 |
| Active Not Recruiting | A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004) Healthy | Phase 1 | 2024-12-20 |
| Recruiting | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Non-Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | 2024-12-20 |
| Completed | A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (M Healthy | Phase 1 | 2024-12-18 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1 Alzheimer Disease, Dementia | Phase 2 | 2024-12-16 |
| Recruiting | A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350- Healthy | Phase 1 | 2024-12-05 |
| Recruiting | A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Coronavirus Disease (COVID-19) | Phase 3 | 2024-12-02 |
| Recruiting | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-0 Metastatic Breast Cancer | Phase 2 | 2024-11-27 |
| Recruiting | Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcer Crohn Disease, Colitis, Ulcerative | Phase 3 | 2024-11-25 |
| Completed | A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032) Healthy, Renal Impairment | Phase 1 | 2024-11-22 |
| Active Not Recruiting | A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic No Lung Cancer, Non-Small Cell Lung Cancer | Phase 3 | 2024-11-21 |
| Completed | A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) Pulmonary Arterial Hypertension | Phase 2 | 2024-11-14 |
| Active Not Recruiting | Safety and Immunogenicity of V540B in Healthy Adults (V540B-002). Healthy | Phase 1 | 2024-11-12 |
| Completed | A Clinical Study of MK-1708 in Healthy Elderly Participants (MK-1708-005) Healthy | Phase 1 | 2024-11-04 |
| Recruiting | Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor0 Gastrointestinal Cancer | Phase 1 / Phase 2 | 2024-11-03 |
| Completed | A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033) Healthy | Phase 1 | 2024-10-21 |
| Recruiting | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small C Carcinoma, Non-Small-Cell Lung | Phase 3 | 2024-10-21 |
| Completed | A Study of MK-2060 in Healthy Participants (MK-2060-016) Venous Thrombosis | Phase 1 | 2024-10-15 |
| Active Not Recruiting | A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alf Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent | Phase 2 | 2024-10-14 |
| Completed | A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Partici Healthy | Phase 1 | 2024-10-07 |
| Completed | A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003) Alzheimer's Disease | Phase 1 | 2024-10-03 |
| Completed | Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020) Healthy | Phase 1 | 2024-10-02 |
| Completed | A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001) Healthy | Phase 1 | 2024-09-25 |
| Completed | Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010) Healthy | Phase 1 | 2024-09-24 |
| Completed | A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030) Hepatic Insufficiency, Hepatic Impairment | Phase 1 | 2024-09-20 |
| Recruiting | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms | Phase 1 / Phase 2 | 2024-09-20 |
| Completed | A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Metastatic Prostate Cancer | Phase 1 | 2024-09-19 |
| Terminated | A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006) Healthy | Phase 1 | 2024-09-09 |
| Completed | A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009) Non-small Cell Lung Cancer | Phase 1 | 2024-09-03 |
| Recruiting | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma | Phase 1 / Phase 2 | 2024-08-16 |
| Recruiting | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker- Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms | Phase 1 / Phase 2 | 2024-08-07 |
| Active Not Recruiting | Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hy Hypercholesterolemia | Phase 3 | 2024-08-05 |
| Completed | Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MAS Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease | Phase 2 | 2024-07-29 |
| Recruiting | A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015) Hepatic Impairment (HI) | Phase 1 | 2024-07-24 |
| Recruiting | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Sec Cervical Cancer | Phase 3 | 2024-07-24 |
| Active Not Recruiting | A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and With Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | 2024-07-17 |
| Completed | A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044) Healthy | Phase 1 | 2024-07-16 |
| Recruiting | Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) Essential Thrombocythemia | Phase 3 | 2024-07-16 |
| Active Not Recruiting | A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tum Neoplasm Metastasis | Phase 1 | 2024-07-14 |
| Active Not Recruiting | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD | Phase 2 | 2024-07-12 |
| Completed | A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011) Prostatic Neoplasms | Phase 1 | 2024-07-11 |
| Completed | A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028) Healthy | Phase 1 | 2024-07-08 |
| Completed | A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetim Hypercholesterolemia | Phase 3 | 2024-07-08 |
| Withdrawn | MSD Belzutifan PAS Von Hippel Lindau Disease | — | 2024-06-30 |
| Completed | A Study of Calderasib (MK-1084) Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Par Healthy | Phase 1 | 2024-06-26 |
| Recruiting | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) Triple-Negative Breast Cancer | Phase 3 | 2024-06-24 |
| Recruiting | A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer | Phase 1 / Phase 2 | 2024-06-20 |
| Completed | A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008) Renal Impairment | Phase 1 | 2024-06-20 |
| Completed | A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015) Healthy | Phase 1 | 2024-06-13 |
| Completed | A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007) Healthy | Phase 1 | 2024-06-13 |
| Completed | Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002) Colitis, Ulcerative | Phase 1 | 2024-06-13 |
| Recruiting | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With E Non-small Cell Lung Cancer (NSCLC) | Phase 3 | 2024-06-11 |
| Recruiting | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous No Non-small Cell Lung Cancer, NSCLC | Phase 3 | 2024-06-10 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease | Phase 3 | 2024-06-05 |
| Recruiting | A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small C Non-small Cell Lung Cancer | Phase 3 | 2024-05-24 |
| Recruiting | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis | Phase 3 | 2024-05-23 |
| Recruiting | Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone i Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | 2024-05-20 |
| Completed | A Study of the Effect of Itraconazole and Phenytoin on Calderasib (MK-1084) in Healthy Adults (MK-1084-008) Healthy | Phase 1 | 2024-05-20 |
| Active Not Recruiting | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma ( Gastroesophageal Cancer | Phase 3 | 2024-05-03 |
| Completed | A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Health Healthy | Phase 1 | 2024-04-23 |
| Completed | A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014) Healthy | Phase 1 | 2024-04-23 |
| Completed | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V9 Carcinoma, Squamous Cell, Skin Neoplasms | Phase 2 / Phase 3 | 2024-04-18 |
| Completed | A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) Malaria | Phase 1 | 2024-04-18 |
| Recruiting | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Breast Neoplasms | Phase 3 | 2024-04-14 |
| Active Not Recruiting | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). Renal Cell Carcinoma | Phase 2 | 2024-04-10 |
| Completed | A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020) Bipolar I Disorder | Phase 1 | 2024-04-08 |
| Recruiting | A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in A Non Small Cell Lung Cancer | Phase 3 | 2024-04-03 |
| Completed | A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026 Healthy | Phase 1 | 2024-04-01 |
| Completed | Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treat Alzheimer's Disease | Phase 1 | 2024-03-28 |
| Active Not Recruiting | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940 Bladder Cancer | Phase 1 / Phase 2 | 2024-03-28 |
| Completed | A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003) Healthy, Narcolepsy | Phase 1 | 2024-03-19 |
| Completed | A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025) Healthy | Phase 1 | 2024-03-18 |
| Completed | A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Par Healthy | Phase 1 | 2024-03-01 |
| Completed | Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) Advanced Solid Tumors | Phase 1 / Phase 2 | 2024-02-28 |
| Completed | A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003) Healthy, Pain | Phase 1 | 2024-02-09 |
| Completed | A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058) Healthy | Phase 1 | 2024-02-07 |
| Completed | A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (m Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | 2024-01-30 |
| Terminated | Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004) Narcolepsy | Phase 1 | 2024-01-24 |
| Completed | A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healt Healthy | Phase 1 | 2024-01-23 |
| Completed | A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023) Healthy | Phase 1 | 2024-01-22 |
| Completed | A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) Pneumococcal Infection | Phase 3 | 2024-01-18 |
| Completed | A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016) Healthy | Phase 1 | 2024-01-17 |
| Withdrawn | Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Human Immunodeficiency Virus, HIV | Phase 2 | 2024-01-04 |
| Recruiting | A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essent Essential Thrombocythemia | Phase 3 | 2023-12-31 |
| Recruiting | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) Prostate Cancer Metastatic | Phase 3 | 2023-12-31 |
| Terminated | Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) Systemic Lupus Erythematosus | Phase 2 | 2023-12-27 |
| Active Not Recruiting | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma | Phase 2 | 2023-12-26 |
| Recruiting | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castrat Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms | Phase 3 | 2023-12-18 |
| Recruiting | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic N Non-small Cell Lung Cancer (NSCLC) | Phase 3 | 2023-12-15 |
| Recruiting | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2023-12-13 |
| Recruiting | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Partic Non-small Cell Lung Cancer | Phase 3 | 2023-12-06 |
| Active Not Recruiting | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) Endometrial Cancer | Phase 3 | 2023-12-06 |
| Terminated | A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) Non-segmental Vitiligo | Phase 2 | 2023-11-27 |
| Completed | A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021) Healthy | Phase 1 | 2023-11-22 |
| Completed | A Study of MK-2225 in Healthy Participants (MK-2225-003) Systemic Sclerosis | Phase 1 | 2023-11-21 |
| Completed | A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) Non-alcoholic Steatohepatitis, Hepatic Impairment | Phase 1 | 2023-11-21 |
| Active Not Recruiting | A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | 2023-11-14 |
| Recruiting | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | 2023-11-12 |
| Completed | A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healt Healthy | Phase 1 | 2023-11-08 |
| Completed | Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-0 HIV, HIV Pre-exposure Prophylaxis | Phase 2 | 2023-11-08 |
| Completed | A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1 Healthy | Phase 1 | 2023-11-07 |
| Completed | A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013) Healthy | Phase 1 | 2023-10-30 |
| Active Not Recruiting | Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Ad Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) | Phase 1 | 2023-10-26 |
| Active Not Recruiting | A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Ulcerative Colitis | Phase 3 | 2023-10-25 |
| Completed | The Effect of Food and Water Volume in Healthy Adult Participants Administered Enlicitide Decanoate (MK-0616) Healthy | Phase 1 | 2023-10-24 |
| Active Not Recruiting | A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidas Squamous Cell Carcinoma | Phase 2 | 2023-10-20 |
| Completed | A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006) Healthy | Phase 1 | 2023-10-17 |
| Active Not Recruiting | Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outc Arteriosclerosis, Hypercholesterolaemia | Phase 3 | 2023-10-09 |
| Completed | A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017) Healthy | Phase 1 | 2023-10-02 |
| Completed | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer | Phase 2 | 2023-09-29 |
| Completed | A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow Healthy | Phase 1 | 2023-09-25 |
| Completed | A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005) Healthy, Narcolepsy | Phase 1 | 2023-09-20 |
| Completed | A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) Healthy | Phase 1 | 2023-09-20 |
| Completed | A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004) Healthy | Phase 1 | 2023-09-18 |
| Completed | A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001) Schizophrenia | Phase 1 | 2023-09-15 |
| Completed | A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007) Hematological Malignancy | Phase 1 | 2023-08-28 |
| Completed | Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4 Influenza Infection | Phase 1 | 2023-08-21 |
| Completed | A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE) Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 1 | 2023-08-14 |
| Completed | A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-01 Hypercholesterolemia, Familial Hypercholesterolemia | Phase 3 | 2023-08-10 |
| Recruiting | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refract Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma | Phase 3 | 2023-08-08 |
| Completed | A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hyperchole Hypercholesterolemia, Familial Hypercholesterolemia | Phase 3 | 2023-08-08 |
| Completed | A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014) Healthy | Phase 1 | 2023-07-25 |
| Completed | A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016) Healthy | Phase 1 | 2023-07-24 |
| Completed | Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020) Hypercholesterolaemia | Phase 1 | 2023-07-20 |
| Active Not Recruiting | A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) Melanoma | Phase 3 | 2023-07-19 |
| Recruiting | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) Metastatic Solid Tumors, Advanced Solid Tumors | Phase 1 | 2023-07-06 |
| Completed | A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009) Healthy | Phase 1 | 2023-06-28 |
| Completed | A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia | Phase 1 | 2023-06-26 |
| Active Not Recruiting | A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in Fir Metastatic Urothelial Carcinoma, Urothelial Neoplasms | Phase 1 / Phase 2 | 2023-06-23 |
| Completed | A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6 Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD | Phase 2 | 2023-06-23 |
| Completed | Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Ol End-Stage Renal Disease (ESRD), End-Stage Kidney Disease (ESKD), Kidney Failure, Chronic | Phase 1 | 2023-06-14 |
| Active Not Recruiting | A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Metastatic Non-small Cell Lung Cancer | Phase 3 | 2023-06-13 |
| Recruiting | Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Heart Failure, Left Ventricular Systolic Dysfunction | Phase 2 / Phase 3 | 2023-05-31 |
| Recruiting | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanc Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2023-05-16 |
| Completed | A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020) Pulmonary Arterial Hypertension | Phase 3 | 2023-05-10 |
| Withdrawn | MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Inf HIV-1, Human Immunodeficiency Virus 1, Immunodeficiency Virus Type 1, Human | Phase 1 | 2023-04-17 |
| Completed | A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Cytomegalovirus Infection | Phase 3 | 2023-03-24 |
| Completed | MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013) Healthy | Phase 1 | 2023-03-20 |
| Active Not Recruiting | A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV- HIV Infection | Phase 3 | 2023-03-17 |
| Active Not Recruiting | Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC St Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease | Phase 2 | 2023-03-16 |
| Active Not Recruiting | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2023-03-16 |
| Completed | A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy | Phase 1 | 2023-03-10 |
| Active Not Recruiting | DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) HIV-1 Infection | Phase 3 | 2023-03-08 |
| Completed | A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0 Healthy | Phase 1 | 2023-03-06 |
| Completed | Single-Ascending Dose Study of MK-2060 in Healthy Chinese Male Adult Participants (MK-2060-009) Healthy | Phase 1 | 2023-03-01 |
| Active Not Recruiting | A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) W HIV-1 Infection | Phase 3 | 2023-02-20 |
| Active Not Recruiting | A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) W HIV-1 Infection | Phase 3 | 2023-02-17 |
| Active Not Recruiting | A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Metastatic Non-small Cell Lung Cancer | Phase 3 | 2023-02-14 |
| Completed | Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) Pneumococcal Infection | Phase 3 | 2023-02-13 |
| Completed | A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002) Mature B-cell Neoplasms | Phase 1 | 2023-02-13 |
| Completed | A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011) End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic | Phase 1 | 2023-02-08 |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab fo Carcinoma, Non-Small-Cell Lung | Phase 3 | 2023-02-06 |
| Completed | A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Health Healthy | Phase 1 | 2023-01-20 |
| Completed | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma Melanoma | Phase 3 | 2023-01-19 |
| Recruiting | Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) Pulmonary Arterial Hypertension | Phase 2 | 2023-01-19 |
| Completed | Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9) Pneumococcal Disease | Phase 3 | 2023-01-10 |
| Completed | A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK Advanced or Metastatic Solid Tumors | Phase 1 | 2022-12-21 |
| Terminated | Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Alzheimer's Disease | Phase 2 | 2022-12-02 |
| Completed | MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004) Human Immunodeficiency Virus | Phase 1 | 2022-11-17 |
| Active Not Recruiting | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | 2022-11-16 |
| Completed | Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STR Pneumococcal Disease | Phase 3 | 2022-11-07 |
| Completed | Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) Respiratory Syncytial Virus | Phase 2 | 2022-11-02 |
| Completed | A Study of MK-0616 in Healthy Adult Participants (MK-0616-009) Hypercholesterolemia | Phase 1 | 2022-10-25 |
| Completed | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1 Hodgkin Lymphoma | Phase 2 | 2022-10-18 |
| Withdrawn | A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035) Human Immunodeficiency Virus (HIV) Infections | Phase 2 | 2022-10-17 |
| Completed | A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012) Healthy, Hypercholesterolemia | Phase 1 | 2022-09-30 |
| Completed | Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Advanced/Metastatic Solid Tumors, Neoplasms | Phase 1 | 2022-09-25 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Pneumonia, Pneumococcal | Phase 3 | 2022-09-23 |
| Completed | A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-0 Alzheimer Disease | Phase 1 | 2022-09-20 |
| Completed | Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003) Dengue Disease, Dengue Virus | Phase 2 | 2022-09-07 |
| Completed | A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011) Healthy | Phase 1 | 2022-09-05 |
| Completed | A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed Healthy | Phase 1 | 2022-08-15 |
| Completed | A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Y Pneumococcal Disease | Phase 3 | 2022-08-12 |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants Renal Cell Carcinoma | Phase 1 / Phase 2 | 2022-08-10 |
| Completed | Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008) Dermatitis, Atopic | Phase 1 | 2022-08-08 |
| Completed | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants W Esophageal Squamous Cell Carcinoma (ESCC) | Phase 1 / Phase 2 | 2022-07-27 |
| Active Not Recruiting | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembr Carcinoma, Renal Cell | Phase 3 | 2022-07-27 |
| Completed | Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma | Phase 2 | 2022-07-25 |
| Active Not Recruiting | V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071) Papillomavirus Infections | Phase 3 | 2022-07-22 |
| Active Not Recruiting | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive an Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma | Phase 2 | 2022-07-21 |
| Active Not Recruiting | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Pl Lymphoma, Large B-Cell, Diffuse (DLBCL) | Phase 2 | 2022-07-14 |
| Completed | Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3) Pneumococcal Infection | Phase 3 | 2022-07-13 |
| Completed | Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7 Pneumococcal Disease | Phase 3 | 2022-07-13 |
| Completed | A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021) End Stage Renal Disease, Renal Impairment | Phase 1 | 2022-07-12 |
| Completed | A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014) Schizophrenia | Phase 1 | 2022-07-12 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced A Pneumonia, Pneumococcal | Phase 3 | 2022-07-12 |
| Terminated | A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tu Advanced Solid Tumors | Phase 1 / Phase 2 | 2022-07-07 |
| Completed | MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation Alzheimer's Disease | Phase 1 | 2022-07-01 |
| Completed | A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003) Renal Impairment | Phase 1 | 2022-06-29 |
| Completed | A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020) Moderate Hepatic Impairment | Phase 1 | 2022-06-24 |
| Active Not Recruiting | A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic So Advanced or Metastatic Solid Tumors | Phase 1 | 2022-06-16 |
| Completed | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previous Colorectal Cancer | Phase 3 | 2022-06-14 |
| Completed | A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016) Hepatic Impairment | Phase 1 | 2022-06-14 |
| Active Not Recruiting | A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies Hematological Malignancies | Phase 1 | 2022-06-09 |
| Completed | MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal D End-Stage Renal Disease, Kidney Failure, Chronic | Phase 1 | 2022-05-30 |
| Completed | A Study of Elpipodect (MK-8189) Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8 Healthy | Phase 1 | 2022-05-13 |
| Completed | Activity Tracking Study in Healthy Volunteers (MK-0000-419) Healthy | Phase 1 | 2022-05-12 |
| Active Not Recruiting | Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) Genital Warts | Phase 3 | 2022-05-07 |
| Active Not Recruiting | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pe Carcinoma, Non-Small-Cell Lung | Phase 3 | 2022-05-03 |
| Completed | Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007) Cognitive Impairment Associated With Schizophrenia | Phase 1 | 2022-04-27 |
| Recruiting | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer ( Colorectal Neoplasms | Phase 3 | 2022-04-02 |
| Completed | Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribon Papillomavirus Infections, Coronavirus Disease (COVID-19) | Phase 3 | 2022-03-28 |
| Completed | Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon Vaccines, Combined, Hexavalent Vaccine | Phase 4 | 2022-03-25 |
| Completed | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembroliz Metastatic Non-Small Cell Lung Cancer | Phase 3 | 2022-03-24 |
| Active Not Recruiting | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment Small Cell Lung Carcinoma | Phase 3 | 2022-03-24 |
| Completed | A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043) Healthy | Phase 1 | 2022-03-23 |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants Carcinoma, Renal Cell | Phase 3 | 2022-03-15 |
| Completed | A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hyperch Hypercholesterolemia, Familial Hypercholesterolemia | Phase 2 | 2022-03-10 |
| Recruiting | Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127 Invasive Fungal Infection | Phase 2 | 2022-02-22 |
| Active Not Recruiting | Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052) Papillomavirus Infections | Phase 3 | 2022-02-18 |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Neoplasms | Phase 3 | 2022-02-03 |
| Recruiting | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed o DLBCL, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | 2022-01-14 |
| Completed | Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in H Pneumococcal Infection | Phase 3 | 2022-01-12 |
| Active Not Recruiting | A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (D Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | 2022-01-08 |
| Recruiting | A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) Advanced Solid Tumors | Phase 1 | 2021-12-17 |
| Active Not Recruiting | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Can Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms | Phase 3 | 2021-12-13 |
| Completed | Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) D RSV Infection | Phase 3 | 2021-11-30 |
| Completed | A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment ( Moderate Renal Impairment | Phase 1 | 2021-11-16 |
| Completed | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previous Colorectal Cancer | Phase 3 | 2021-11-10 |
| Completed | A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFr Chronic Heart Failure With Reduced Ejection Fraction | Phase 3 | 2021-11-02 |
| Active Not Recruiting | A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Synd PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | Phase 2 | 2021-11-02 |
| Completed | A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) Ulcerative Colitis | Phase 1 | 2021-10-14 |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or With Renal Cell Carcinoma | Phase 1 | 2021-10-13 |
| Completed | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Classical Hodgkin Lymphoma | Phase 2 | 2021-10-07 |
| Completed | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-0 Hematological Malignancies | Phase 2 | 2021-09-28 |
| Terminated | A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leu Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia | Phase 1 | 2021-09-26 |
| Active Not Recruiting | A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembroli Advanced or Metastatic Solid Tumors | Phase 1 | 2021-09-21 |
| Completed | Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Rece End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic | Phase 2 | 2021-09-17 |
| Completed | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck | Phase 2 | 2021-09-16 |
| Active Not Recruiting | Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodefic HIV-1 Infection | Phase 3 | 2021-09-15 |
| Recruiting | Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-34 Small Cell Lung Carcinoma | Phase 1 / Phase 2 | 2021-08-19 |
| Active Not Recruiting | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Neoplasm Malignant | Phase 2 | 2021-08-18 |
| Recruiting | Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocr Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease | Phase 2 | 2021-08-12 |
| Completed | Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) Coronavirus Disease (COVID-19) | Phase 3 | 2021-08-11 |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Pla Non-Small Cell Lung Cancer | Phase 3 | 2021-08-05 |
| Completed | A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001 Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | 2021-08-04 |
| Active Not Recruiting | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participan Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | 2021-07-28 |
| Completed | Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Lin Small Cell Lung Cancer | Phase 2 | 2021-07-15 |
| Active Not Recruiting | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Colorectal Cancer | Phase 2 | 2021-06-25 |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recu Breast Neoplasms | Phase 3 | 2021-06-18 |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) Carcinoma, Renal Cell | Phase 1 | 2021-06-14 |
| Completed | A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Phase 2 | 2021-06-07 |
| Completed | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versu Metastatic Hormone-Sensitive Prostate Cancer | Phase 3 | 2021-05-25 |
| Terminated | Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resi Treatment Resistant Depression | Phase 2 | 2021-05-20 |
| Completed | A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertens Pulmonary Arterial Hypertension, Hypertension, Pulmonary | Phase 2 / Phase 3 | 2021-05-19 |
| Completed | Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V50 Papillomavirus Infections | Phase 3 | 2021-05-17 |
| Recruiting | A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) Pulmonary Arterial Hypertension | Phase 3 | 2021-05-12 |
| Completed | Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Melanoma | Phase 1 / Phase 2 | 2021-05-03 |
| Completed | Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplat Bladder Cancer | Phase 3 | 2021-04-21 |
| Completed | Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Metastatic Non Small Cell Lung Cancer | Phase 2 | 2021-04-20 |
| Active Not Recruiting | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembr Carcinoma, Renal Cell | Phase 3 | 2021-04-14 |
| Completed | Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) Respiratory Syncytial Virus Infection | Phase 2 / Phase 3 | 2021-04-07 |
| Completed | Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programm Lung Neoplasms, Non-Small-Cell Lung Carcinoma | Phase 3 | 2021-04-07 |
| Recruiting | Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma | Phase 2 | 2021-04-05 |
| Completed | Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Par Colorectal Neoplasms | Phase 3 | 2021-03-29 |
| Completed | Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413) Alzheimer's Disease, Mild Cognitive Impairment | Phase 1 | 2021-03-23 |
| Completed | A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012) Hepatic Impairment | Phase 1 | 2021-03-17 |
| Completed | Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080 Advanced Hepatocellular Carcinoma | Phase 2 | 2021-03-16 |
| Active Not Recruiting | Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-0 Papillomavirus Infections | Phase 3 | 2021-03-15 |
| Terminated | Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are HIV Preexposure Prophylaxis | Phase 3 | 2021-03-15 |
| Completed | Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Supp HIV-1 Infection | Phase 2 | 2021-03-09 |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma, Renal Cell | Phase 3 | 2021-02-25 |
| Terminated | Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis | Phase 3 | 2021-02-24 |
| Completed | Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRC Renal Cell Carcinoma | Phase 2 | 2021-02-23 |
| Completed | MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005) Alzheimer's Disease | Phase 1 | 2021-02-16 |
| Completed | Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036) Pneumococcal Disease | Phase 3 | 2021-02-10 |
| Terminated | Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Renal Impairment | Phase 1 | 2021-02-10 |
| Completed | Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adu Pneumococcal Infection | Phase 1 | 2021-02-04 |
| Recruiting | Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg Human Immunodeficiency Virus (HIV) Infection | Phase 2 | 2021-02-03 |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Par Endometrial Neoplasms | Phase 3 | 2021-01-10 |
| Active Not Recruiting | Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participan Advanced/Metastatic Gastroesophageal Adenocarcinoma | Phase 3 | 2020-12-30 |
| Active Not Recruiting | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Carcinoma, Renal Cell | Phase 1 / Phase 2 | 2020-12-17 |
| Active Not Recruiting | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Carcinoma, Renal Cell | Phase 1 / Phase 2 | 2020-12-16 |
| Completed | Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008) Schizophrenia | Phase 2 | 2020-12-15 |
| Active Not Recruiting | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab an Small Cell Lung Cancer | Phase 3 | 2020-12-08 |
| Completed | Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064) Warts, Genital, Neoplasms, Anal | Phase 3 | 2020-11-30 |
| Completed | Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who HIV-1 Infection | Phase 2 | 2020-11-26 |
| Terminated | A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) Nonalcoholic Steatohepatitis | Phase 2 | 2020-11-11 |
| Completed | Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030) Human Immunodeficiency Virus (HIV) Infection | Phase 1 | 2020-11-05 |
| Completed | A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention Head and Neck Squamous Cell Carcinoma | Phase 3 | 2020-10-30 |
| Terminated | Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001) Coronavirus Disease (COVID-19) | Phase 1 | 2020-10-29 |
| Terminated | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metas Neoplasm Metastasis | Phase 1 / Phase 2 | 2020-10-28 |
| Completed | A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metast Squamous Cell Carcinoma of Head and Neck | Phase 4 | 2020-10-27 |
| Completed | Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at Hig Delirium | Phase 3 | 2020-10-22 |
| Terminated | Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001) Coronavirus Disease (COVID-19) | Phase 2 / Phase 3 | 2020-10-19 |
| Completed | Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-00 Coronavirus Disease (COVID-19) | Phase 2 / Phase 3 | 2020-10-19 |
| Completed | Islatravir and Methadone Pharmacokinetics (MK-8591-029) HIV-1 Infection | Phase 1 | 2020-10-16 |
| Terminated | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Prostatic Neoplasms | Phase 3 | 2020-09-23 |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) Carcinoma, Renal Cell | Phase 2 | 2020-09-13 |
| Completed | V114 and Acute Otitis Media (V114-032/PNEU-ERA) Acute Otitis Media (AOM) | Phase 3 | 2020-09-12 |
| Completed | A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013) Hepatitis B | Phase 3 | 2020-09-02 |
| Completed | Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Par Schizophrenia | Phase 1 | 2020-08-28 |
| Completed | Gluten Challenge Study in Celiac Disease Participants (MK-0000-402) Celiac Disease | EARLY_Phase 1 | 2020-08-28 |
| Terminated | A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants Coronavirus Disease (COVID-19) | Phase 1 / Phase 2 | 2020-08-27 |
| Completed | Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9 | Phase 3 | 2020-08-25 |
| Completed | Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyr Metastatic Colorectal Cancer | Phase 3 | 2020-08-19 |
| Completed | Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatini Squamous Cell Carcinoma of Head and Neck | Phase 2 | 2020-08-06 |
| Completed | A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7 Relapsed or Refractory Solid Tumors | Phase 2 | 2020-07-30 |
| Completed | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastr Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | 2020-07-29 |
| Completed | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line In Malignant Melanoma | Phase 3 | 2020-07-14 |
| Completed | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Ad Biliary Tract Carcinoma | Phase 3 | 2020-07-10 |
| Withdrawn | Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009) Coronavirus Disease 2019 (COVID-19), Pneumonia, Hypoxemia | Phase 1 | 2020-07-07 |
| Active Not Recruiting | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olapar Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 3 | 2020-07-06 |
| Completed | Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104) Invasive Aspergillosis | Phase 2 | 2020-07-02 |
| Completed | Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033) Pneumococcal Infections | Phase 3 | 2020-07-01 |
| Active Not Recruiting | Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Melanoma | Phase 1 / Phase 2 | 2020-07-01 |
| Completed | Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Melanoma | Phase 1 / Phase 2 | 2020-06-26 |
| Completed | A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cel Lymphoma, B-Cell | Phase 1 | 2020-06-26 |
| Completed | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants Melanoma | Phase 1 / Phase 2 | 2020-06-26 |
| Completed | Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026) Human Immunodeficiency Virus (HIV) Infection | Phase 1 | 2020-06-18 |
| Completed | Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmona Pulmonary Hypertension | Phase 1 | 2020-06-05 |
| Terminated | Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pe Advanced/Metastatic Melanoma | Phase 2 | 2020-06-05 |
| Active Not Recruiting | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarteri Carcinoma, Hepatocellular | Phase 3 | 2020-05-22 |
| Completed | Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043 Chronic Cough | Phase 3 | 2020-05-21 |
| Active Not Recruiting | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Urinary Bladder Neoplasms | Phase 3 | 2020-05-19 |
| Completed | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervi Uterine Cervical Neoplasms | Phase 3 | 2020-05-12 |
| Completed | Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-72 Chronic Cough | Phase 3 | 2020-05-10 |
| Completed | Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK- Nosocomial Pneumonia | Phase 1 | 2020-04-17 |
| Completed | Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency HIV-1 Infection | Phase 3 | 2020-03-18 |
| Completed | Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | 2020-03-04 |
| Completed | Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and T HIV-1 Infection | Phase 3 | 2020-02-28 |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Ch Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC) | Phase 3 | 2020-02-28 |
| Active Not Recruiting | A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482- Carcinoma, Renal Cell | Phase 3 | 2020-02-27 |
| Active Not Recruiting | Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vac Papillomavirus Infections | Phase 3 | 2020-02-27 |
| Completed | Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With HIV Infection | Phase 3 | 2020-02-18 |
| Completed | Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) HIV Infection | Phase 3 | 2020-02-18 |
| Active Not Recruiting | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versu Metastatic Hormone-Sensitive Prostate Cancer | Phase 3 | 2020-02-12 |
| Completed | A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention Head and Neck Squamous Cell Carcinoma | Phase 3 | 2020-02-05 |
| Completed | KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational A Carcinoma, Non-Small-Cell Lung | Phase 2 | 2020-01-21 |
| Completed | MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Cytomegalovirus Infection, Cytomegalovirus Disease | Phase 3 | 2019-12-27 |
| Completed | KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational A Carcinoma, Non-Small-Cell Lung | Phase 2 | 2019-12-19 |
| Recruiting | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy W Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | 2019-12-19 |
| Recruiting | KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alon Carcinoma, Non-Small-Cell Lung | — | 2019-12-19 |
| Completed | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Ch Triple Negative Breast Neoplasms | Phase 2 | 2019-12-19 |
| Completed | A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelio Mesothelioma | Phase 1 | 2019-12-09 |
| Completed | A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001) Pneumonia, Pneumococcal | Phase 1 / Phase 2 | 2019-12-06 |
| Active Not Recruiting | Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombi Solid Tumors | Phase 2 | 2019-11-18 |
| Completed | Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU- Pneumococcal Infections | Phase 3 | 2019-11-05 |
| Completed | Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenv Nonsquamous Non-small Cell Lung Cancer | Phase 3 | 2019-11-05 |
| Terminated | A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Pa Neoplasm Metastasis | Phase 1 | 2019-11-04 |
| Completed | Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participa Respiratory Syncytial Viruses | Phase 2 | 2019-10-28 |
| Completed | Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Non-small Cell Lung Cancer | Phase 3 | 2019-10-23 |
| Completed | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-e Endometrial Neoplasms | Phase 3 | 2019-10-22 |
| Completed | Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Suspected or Documented Gram-negative Bacterial Infection | Phase 2 / Phase 3 | 2019-10-08 |
| Completed | Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059) Type 2 Diabetes Mellitus | Phase 3 | 2019-10-08 |
| Withdrawn | Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Alzheimer's Disease, Mild Cognitive Impairment | Phase 1 | 2019-09-27 |
| Completed | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Ad Biliary Tract Carcinoma | Phase 3 | 2019-09-24 |
| Completed | Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Imm HIV-1 Infection | Phase 2 | 2019-09-19 |
| Completed | Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chemotherapy-induced Nausea and Vomiting | Phase 4 | 2019-09-09 |
| Completed | Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) Pneumococcal Infections | Phase 3 | 2019-09-04 |
| Completed | Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-02 Pneumococcal Infections | Phase 3 | 2019-08-28 |
| Completed | Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation ( Cytomegalovirus (CMV) Infection | Phase 2 | 2019-08-08 |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metas Prostatic Neoplasms | Phase 3 | 2019-07-28 |
| Active Not Recruiting | Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin P Urinary Bladder Cancer, Muscle-invasive | Phase 3 | 2019-07-24 |
| Completed | Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pedia Neuromuscular Blockade | Phase 4 | 2019-07-23 |
| Completed | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsq Carcinoma, Nonsquamous Non-small-cell Lung | Phase 3 | 2019-06-28 |
| Completed | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non- Carcinoma, Squamous Cell, Non-small-cell Lung | Phase 3 | 2019-06-28 |
| Terminated | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms | Phase 1 | 2019-06-26 |
| Completed | Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants W Metastatic Non-Small Cell Lung Cancer | Phase 3 | 2019-06-26 |
| Active Not Recruiting | Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) Papillomavirus Infections | Phase 3 | 2019-06-26 |
| Terminated | Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Non-Small Cell Lung Cancer | Phase 3 | 2019-06-25 |
| Completed | Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) Pneumococcal Infections | Phase 3 | 2019-06-25 |
| Completed | Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (C Cytomegalovirus Infection | Phase 3 | 2019-06-21 |
| Completed | A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advance Neoplasms | Phase 1 | 2019-06-19 |
| Completed | Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) Pneumococcal Infections, Pneumococcal Vaccines | Phase 3 | 2019-06-19 |
| Completed | Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) Pneumococcal Infections | Phase 3 | 2019-06-13 |
| Active Not Recruiting | Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuv Bladder Cancer | Phase 3 | 2019-06-13 |
| Completed | Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) Pneumococcal Infections, Pneumonia, Pneumococcal | Phase 3 | 2019-06-12 |
| Completed | Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatoc Hepatocellular Carcinoma | Phase 3 | 2019-05-28 |
| Completed | A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension Chronic Cough | Phase 3 | 2019-05-17 |
| Completed | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin- Urothelial Carcinoma | Phase 3 | 2019-05-06 |
| Completed | Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castra Prostatic Neoplasms | Phase 3 | 2019-05-02 |
| Completed | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Prostatic Neoplasms | Phase 3 | 2019-05-02 |
| Completed | Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK- Renal Dialysis, Kidney Failure, Chronic | Phase 1 | 2019-04-29 |
| Completed | Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years Papillomavirus Infections | Phase 3 | 2019-04-27 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral HIV-1 Infection | Phase 1 | 2019-04-26 |
| Completed | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-e Endometrial Neoplasms | Phase 3 | 2019-04-11 |
| Completed | Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039) Obstructive Sleep Apnea (OSA) | Phase 1 | 2019-04-10 |
| Completed | Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) Pneumococcal Infections | Phase 1 | 2019-04-02 |
| Completed | Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced C Carcinoma, Squamous Cell | Phase 3 | 2019-04-01 |
| Completed | Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenv Nonsquamous Non-small Cell Lung Cancer | Phase 3 | 2019-03-25 |
| Completed | Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra- Complicated Intra-abdominal Infections | Phase 3 | 2019-03-20 |
| Terminated | Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metas Advanced/Metastatic Solid Tumors | Phase 1 | 2019-03-18 |
| Completed | Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Non-small Cell Lung Cancer | Phase 3 | 2019-03-13 |
| Completed | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line In Malignant Melanoma | Phase 3 | 2019-03-12 |
| Completed | Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003) Cytomegalovirus Infections | Phase 1 | 2019-03-08 |
| Completed | Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058) Varicella | Phase 3 | 2019-03-01 |
| Completed | Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) Merkel Cell Carcinoma | Phase 3 | 2019-02-25 |